Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Consolidative Radiotherapy Combined With Camrelizumab and Chemotherapy for Oligometastatic Nasopharyngeal Carcinoma: A Multicenter, Open-Label, Phase II Trial (NPC-CR01)

NCT05128201 is registered in ClinicalTrials.gov with Jiangxi Provincial Cancer Hospital as lead sponsor.

NCT NCT05128201
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05128201 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Consolidative Radiotherapy Combined With Camrelizumab and Chemotherapy for Oligometastatic Nasopharyngeal Carcinoma: A Multicenter, Open-Label, Phase II Trial (NPC-CR01)
Lead sponsor
Jiangxi Provincial Cancer Hospital
Phase
Phase 2
Overall status
Unknown status
Start date
December 1, 2021
Completion date
May 31, 2026
Enrollment
63 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

oligometastatic disease